Skip to main content
D. Yin on Muck Rack

D. Yin

As seen in: Wiley Online Library, Annals of Oncology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with D.

Contact D., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Semaglutide‐Induced Hepatic Injury: A Rare Case of Drug Induced Liver Injury

|
By S. Dhillon, D. Yin, Rupayan Kundu, Lyudmila Shtoff
| Wiley Online Library Verified
Although semaglutide is typically hepatoprotective and rarely associated with liver injury, clinicians should remain vigilant for idiosyncratic drug-induced liver injury (DILI). In patients with unexplained liver enzyme elevations during semaglutide initiation or dose increase, prompt discontinuation often leads to rapid normalization, underscoring the importance of monitoring hepatic function closely.
Open in Who Shared Issue with article?

A randomized comparative study of PF-05280586 (a potential biosimilar) vs rituximab for patients with CD20 + , low tumor burden, follicular lymphoma

|
By I. Jacobs, M. Suster, B. Jin, D. Yin
| Annals of Oncology Verified
Background: Use of single-agent rituximab may provide a useful alternative to watchful waiting by delaying the time to initiation of chemotherapy in patients with low tumor burden follicular lymphoma (LTB-FL). However, access to biologics like rituximab can be restricted. Biosimilars to rituximab represent a potential opportunity to increase patient access and lower treatment cost.
Open in Who Shared Issue with article?
See all 2 articles